A case with recovery of response to tolvaptan associated with remission of acute kidney injury and increased urine osmolality

International Heart Journal

Volumn 54, Issue 2, 2013, Pages 115-118

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Kato, Naoko ^a   Minatsuki, Shun ^a   Muraoka, Hironori ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Shiga, Taro ^a   Hatano, Masaru ^a   Hosoya, Yumiko ^a   Takahashi, Masao ^a   Yao, Atsushi ^a   Kyo, Shunei ^a   Ono, Minoru ^a   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Heart failure; Rejection; Renal dysfunction; Vasopressin

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; FUROSEMIDE; IMMUNOGLOBULIN; INOTROPIC AGENT; METHYLPREDNISOLONE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RITUXIMAB; TOLVAPTAN;

ACUTE KIDNEY FAILURE; ADOLESCENT; ARTICLE; CARDIAC GRAFT REJECTION; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG PULSE THERAPY; DYSPNEA; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE INJURY; HEART TRANSPLANTATION; HUMAN; LYMPHOCYTIC INFILTRATION; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; TUBULAR DYSFUNCTION; URINE OSMOLALITY; URINE VOLUME;

ACUTE KIDNEY INJURY; ADOLESCENT; BENZAZEPINES; FEMALE; HEART FAILURE; HUMANS; OSMOLAR CONCENTRATION; RECEPTORS, VASOPRESSIN;

EID: 84875878721     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.54.115     Document Type: Article

References (20)

1. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56: 1527-34. (Review)
2. Basraon J, Deedwani PC. Diuretics in heart failure: practical considerations. Med Clin North Am 2012; 96: 933-42. (Review)
3. MacFadyen RJ, Gorski JC, Brater DC, Struthers AD. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol 2004; 57: 622-31.
4. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981; 305: 263-6.
5. Kinugawa K. How to treat stage D heart failure?-When to implant left ventricular assist devices in the era of continuous flow pumps?-. Circ J 2011; 75: 2038-45. (Review)
6. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25 Suppl 1: S33-45.
7. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25 Suppl 1: S57-65.
8. Watanabe K, Dohi K, Sugimoto T, et al. Short-term effects of lowdose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012; 60: 462-9.
9. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-5.
10. Imamura T, Kinugawa K, Shiga T, et al. Correction of hyponatremia by tolvaptan before left ventricular assist device implantation. Int Heart J 2012; 53: 391-3.
11. Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011; 7: 151-61. (Review)
12. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria with urine osmolality effectively predict responses to tolvaptan in decompensated heart failure patients-an association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.
13. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
14. Bichet DG, Oksche A, Rosenthal W. Congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1997; 8: 1951-8. (Review)
15. Carvounis CP, Nisar S, Guro-Razuman S. Significance of the frac tional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int 2002; 62: 2223-9.
16. Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review. Am Fam Physician 2005; 71: 1153-62. (Review)
17. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinaseassociated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012; 50: 1505-17.
18. Gullestad L, Iversen M, Mortensen SA, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010; 89: 864-72.
19. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153-9. (Review)
20. Miller RL, Kohan DE. Hypoxia regulates endothelin-1 production by the inner medullary collecting duct. J Lab Clin Med 1998; 131: 45-8.